Fig. 4: Oligomeric sE2-cVLPs present less AR2A epitopes than monomeric sE2-cVLPs and induces significantly less AR1B- and AR2A-specific antibodies in mice. | npj Vaccines

Fig. 4: Oligomeric sE2-cVLPs present less AR2A epitopes than monomeric sE2-cVLPs and induces significantly less AR1B- and AR2A-specific antibodies in mice.

From: Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers

Fig. 4

Dose-response ELISAs against cVLPs coupled either to (A) monomeric or (B) oligomeric sE2 using human monoclonal anti-HCV antibodies AR1B, AR2A, or AR3A. ELISAs were done in single replicates using anti-human IgG coupled to HRP and subsequently, a colorimetric TMB substrate signal was detected. C–E Competition ELISAs were performed using week 6 mouse sera in two replicates in a 3-fold dilution series, starting at 1:200, to block binding of AR1B, AR2A, or AR3A (see Supplementary Fig. 2 for full dose-response analysis). Residual binding was calculated by comparing to wells without blocking serum and converted to percent. Values represent mean and the error bars represent the standard deviation. Pre-immune sera were shown to have no inhibitory effect for the three tested antibodies (Supplementary Fig. 2). Statistical significance testing was done using non-parametric Mann–Whitney tests (Graphpad Prism 9.2.0) with a significance threshold set at 95%.

Back to article page